Radioimmunotherapy (RIT) in Brain Tumors / 대한핵의학회잡지
Korean Journal of Nuclear Medicine
;
: 374-381, 2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-786504
ABSTRACT
Annually, the incidence of brain tumors has slightly increased and also the patient prognosis is still disappointing, especially for high-grade neoplasms. So, researchers seek methods to improve therapeutic index as a critical aim of treatment. One of these new challenging methods is radioimmunotherapy (RIT) that involves recruiting a coupling of radionuclide component with monoclonal antibody (mAb) which are targeted against cell surface tumor–related antigens or antigens of cells within the tumor microenvironment. In the context of cancer care, precision medicine is exemplified by RIT; precision medicine can offer a tailored treatment to meet the needs for treatment of brain tumors. This review aims to discuss the molecular targets used in radioimmunotherapy of brain tumors, available and future radioimmunopharmaceutics, clinical trials of radioimmunotherapy in brain neoplasms, and eventually, conclusion and future perspective of application of radioimmunotherapy in neurooncology cancer care.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pronóstico
/
Encéfalo
/
Neoplasias Encefálicas
/
Incidencia
/
Radioinmunoterapia
/
Medicina de Precisión
/
Microambiente Tumoral
Tipo de estudio:
Estudio de incidencia
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Korean Journal of Nuclear Medicine
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS